Yang Eu Jeen, Park Kyung Mi, Kim Yoo-Mi, Jung Ki Sun, Lim Young Tak, Cheon Chong Kun
Departments of Pediatrics.
Internal Medicine, Division of Hematology-Oncology, Pusan National University Yangsan Hospital, Yangsan, Korea.
J Pediatr Hematol Oncol. 2020 Apr;42(3):e188-e192. doi: 10.1097/MPH.0000000000001430.
May-Hegglin anomaly (MHA) is a rare autosomal dominant disorder caused by a mutation in the myosin heavy chain 9 (MYH9) gene. MHA patients have variable clinical manifestations including thrombocytopenia, renal injury, hearing impairment, and cataracts. We describe a 25-year-old man with isolated thrombocytopenia initially. He experienced recurrent seizures with stable thrombocytopenia after the first seizures related to intracranial hemorrhage. He was identified a novel c.3452C>T mutation by targeted exome sequencing. If a patient with thrombocytopenia shows recurrent seizures as well as renal, hearing, visual symptoms, MHA should be suspected and the targeted exome sequencing is considered an effective diagnostic tool.
May-Hegglin异常(MHA)是一种罕见的常染色体显性疾病,由肌球蛋白重链9(MYH9)基因突变引起。MHA患者有多种临床表现,包括血小板减少、肾损伤、听力障碍和白内障。我们最初描述了一名25岁的孤立性血小板减少男性患者。在首次与颅内出血相关的癫痫发作后,他经历了癫痫复发且血小板减少稳定。通过靶向外显子组测序,他被鉴定出一种新的c.3452C>T突变。如果血小板减少患者出现癫痫复发以及肾、听力、视觉症状,应怀疑MHA,靶向外显子组测序被认为是一种有效的诊断工具。